| Description | TAT-DEF-Elk-1 is a cell-penetrating peptide Elk-1 inhibitor. |
| In vitro | Elk-1 phosphorylation on Ser383/389 has a dual function and triggers both Elk-1 nuclear translocation and SRE-dependent gene expression. TAT-DEF-Elk-1 (5 μM; 2 hours) treatment shows significant inhibition of c-Fos, Zif268, and JunB, but has no effects on c-Jun expression. TAT-DEF-Elk-1 (5-10 μM; 1 hour) specifically inhibits glutamate-induced elk-1 activation and does not interfere with ERK, MSK-1, or CREB phosphorylation [1]. |
| In vivo | TAT-DEF-Elk-1 (i.p.; 1mg/kg; daily; 14 days) reflects antidepressant efficacy in mice, it decreases immobility similar to the antidepressant desipramine and fluoxetine [2]. |
| Target activity | ELK1: |
| Synonyms | TDE |
| molecular weight | 3561.136 |
| Molecular formula | C155H259N57O40 |
| CAS | 1220751-16-5 |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Lavaur J, et al. A TAT-DEF-Elk-1 peptide regulates the cytonuclear trafficking of Elk-1 and controls cytoskeleton dynamics.J Neurosci. 2007 Dec 26;27(52):14448-58. 2. Apazoglou K, et al. Antidepressive effects of targeting ELK-1 signal transduction.Nat Med. 2018 May;24(5):591-597. |